Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 92 results found. Search for [ COVID-19 antibody drug ]

Results 1 to 21 of 92
PTI
December 27, 2020
Serum Institute of India (SII) has made a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine. The SII has already manufactured 40 million doses of the vaccine


PTI
December 27, 2020
Tthe researchers in the Storm Chase study believe a Long-Acting AntiBody (LAAB) known as AZD7442, developed by AstraZeneca, may offer immediate and long-term protection to people who have been recently exposed to coronavirus


BusinessToday.In
December 16, 2020
Rapid antigen detection test directly detects presence or absence of coronavirus antigen in patient's body, generating results in 15-20 minutes; ICMR-approved CIPtest is found to have specificity and sensitivity of 98.09 per cent and up to 75 per cent


BusinessToday.In
December 11, 2020
The mRNA vaccine candidate -  HGCO19 - is being developed by Pune-based company Gennova, and is supported with seed grant under the Ind-CEPI mission of Department of Biotechnology under Ministry of Science and Technology


Reuters
December 3, 2020
The new purchase is part of a US government deal to secure nearly 1 million doses of Lilly's bamlanivimab


PB Jayakumar & Joe C Mathew
New Delhi, November 25, 2020
A blow-by-blow account of how Indian vaccines are being readied


BusinessToday.In
November 25, 2020
India Stock Market Highlights Today: Global equities were mostly buoyed today encouraged by news on the development of coronavirus vaccines and more assurance for a transition of power in the US to President-elect Joe Biden


Reuters
November 22, 2020
The agency said the antibodies are not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19


PB Jayakumar
November 18, 2020
Cipla will sell these kits across 25 markets in Asia, Middle-East and North Africa, Latin America, EU and Australia


BusinessToday.In
November 11, 2020
COVAXIN's phase-3 trial at AMU is aimed at checking the safety and effectiveness of the COVID-19 vaccine, jointly developed by the Hyderabad-headquartered Bharat Biotech, National Institute of Virology (NIV) and Indian Council of Medical Research (ICMR)


Reuters
November 11, 2020
The Food and Drug Administration (FDA) granted emergency use authorization (EUA) to Eli Lilly & Co's bamlanivimab based on trial data


BusinessToday.In
November 9, 2020
Researchers made their discovery while developing highly sensitive antibody tests for COVID-19. They compared the blood of COVID-19 patients with that of patients who had not had the disease


Chitranjan Kumar
November 6, 2020
Cipla Q2 results: India business grew by 17 per cent YoY and 33 per cent QoQ on the back of strong growth across businesses and continued servicing of patients with COVID-19 portfolio


PB Jayakumar
November 3, 2020
Zydus today said it has filed an Investigational New Drug (IND) application for 'ZYIL1', an oral drug candidate, that has found to be effective in pre-clinic studies to control inflammation in COVID-19 related diseases


PTI
October 31, 2020
Responding to a complaint by RTI activist Saket Gokhale, the commission said it has found no violation of the provisions of the model code in the issue


PTI
October 31, 2020
Regeneron Pharmaceuticals Inc. said Friday that independent monitors had recommended placing on hold enrollment of the most severely ill patients


BusinessToday.In
October 29, 2020
Stocks to watch today on October 29: Wipro, Hero MotoCorp, GSK Pharma, SBI, L&T among others are the top stocks to watch out for in Thursday's trading session


Chitranjan Kumar
October 28, 2020
Validated and approved by ICMR and the National Institute of Virology (NIV), Pune, Cipla's ELIfast is found to have specificity and sensitivity of 99.33 per cent and 92 per cent, respectively


PTI
October 27, 2020
Speaking to reporters after a meeting with AstraZeneca Managing Director Gagan Singh Bedi, he said the first phase of trials of the vaccine were encouraging


Reuters
October 27, 2020
President Donald Trump received a similar experimental antibody drug from Regeneron Pharmaceuticals Inc on an emergency basis when he was sickened with the coronavirus earlier this month


PAGES 1 OF 5  12345